Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report. The quarterly sales came in a bit lower than expected; however, operating expenses were a bit better than anticipated. We will provide a research update shortly, where we will dig deeper into the report, likely making some downward changes to our short-term sales estimates.
LÄS MER
